Canine Parvovirus

Overview and Taxonomy of Canine Parvovirus

Taxonomic Classification and Virion Structure

Canine parvovirus type 2 (CPV-2) is classified within the family Parvoviridae, subfamily Parvovirinae, genus Protoparvovirus, and species Carnivore protoparvovirus 1 [12, 14, 31]. This taxonomic placement situates CPV-2 alongside other significant pathogens, including feline panleukopenia virus (FPV), mink enteritis virus, and raccoon parvovirus, all of which share a common ancestry and considerable genomic homology [9, 25]. The virus is characterized as a non-enveloped, single-stranded DNA (ssDNA) virus with an icosahedral capsid symmetry, approximately 25–30 nm in diameter [14, 40]. The capsid displays a rough surface composed of triangular subunits, a structural feature that facilitates both environmental stability and host cell receptor interactions [14]. The viral genome is linear, approximately 5,200 nucleotides in length, and encodes two open reading frames (ORFs): one encompassing the non-structural proteins NS1 and NS2, which are essential for viral DNA replication and cytotoxicity, and the other encoding the structural proteins VP1 and VP2, with VP2 constituting the primary immunogenic capsid component [10, 13, 14, 30]. VP2 is of paramount importance not only for antibody neutralization but also as the principal determinant of host range and tissue tropism [8, 40].

Emergence and Evolutionary Origin

The emergence of CPV-2 as a novel pathogen in the domestic dog population is a seminal event in veterinary virology. In the late 1970s, a feline panleukopenia-like virus, likely of wild carnivore origin, underwent a cross-species spillover event into canids, resulting in a global pandemic of acute hemorrhagic gastroenteritis and myocarditis [4, 15, 24]. The original CPV-2 strain was first identified in 1978 and spread with remarkable speed across all continents within a matter of years [15, 28, 40]. Unlike many RNA viruses, CPV-2 possesses a DNA genome; however, it exhibits a substitution rate approaching that of RNA viruses, a phenomenon attributed to the high replication fidelity errors inherent in its DNA polymerase and the constraints of a compact genome under strong selective pressure [8, 33, 40]. Despite 40 years of sustained pandemic circulation, nucleotide identity among CPV-2 variants remains remarkably high, greater than 99%, with fewer than 40 fixed substitutions accumulating across the entire genome [15]. This suggests that a limited number of key mutations, rather than extensive genetic drift, have driven the virus’s adaptation and sustained transmission in the canine host.

Antigenic Variants and Nomenclature

Shortly after its emergence, the original CPV-2 underwent rapid antigenic and genetic diversification, leading to the replacement of the original strain by three distinct antigenic variants: CPV-2a, CPV-2b, and CPV-2c [2, 5, 12, 14, 35]. These variants are defined predominantly by specific amino acid substitutions at residue 426 of the VP2 capsid protein: CPV-2a carries asparagine (Asn), CPV-2b carries aspartic acid (Asp), and CPV-2c carries glutamic acid (Glu) [16, 38]. The nomenclature, while widely used, has been subject to debate, as the classification based on a single amino acid residue does not fully capture the phylogenetic complexity of circulating strains [27, 33, 35]. Indeed, researchers have increasingly recognized that CPV-2a, -2b, and -2c represent antigenic sub-lineages within a broader CPV-2a clade, and that phylogenetic analysis using full VP2 gene sequences provides a more robust framework for understanding viral evolution [33, 34]. Globally, CPV-2c has demonstrated a tendency to replace CPV-2a as the dominant variant in Asia, South America, North America, and parts of Africa [2, 7, 11, 39], though considerable regional variation persists. For instance, CPV-2a remains prevalent in parts of India [13] and was the dominant genotype in Italy for many years before CPV-2c became more frequent [28, 34].

Genetic Diversity and Emergent Sub-Variants

Beyond the canonical 426 residue, the VP2 gene harbors numerous other sites of evolutionary significance that influence antigenicity, receptor binding, and potential vaccine escape. Among the most well-characterized additional mutations are Ala5Gly, Phe267Tyr, Tyr324Ile, Gln370Arg, and Thr440Ala [2, 7, 17, 35, 40]. The simultaneous presence of mutations at positions 5, 267, 324, and 370, particularly in CPV-2c strains, defines a distinctive “Asian-origin” cluster that has been progressively expanding its geographic footprint [6, 17, 18, 22, 30]. These Asian-derived CPV-2c mutants have been documented not only throughout East and Southeast Asia (China, Taiwan, Thailand, Vietnam, Korea) [18, 20, 23, 39, 43] but have also been introduced into Europe through dog importation, with reports in Italy, Romania, and Nigeria [6, 17, 22, 30]. The emergence and spread of these sub-variants underscore the dynamic evolutionary trajectory of CPV-2 and raise important questions about the long-term efficacy of existing vaccines, which are based on older CPV-2 or CPV-2b strains [1, 5, 8, 21]. In addition to the 426-based classification, the VP2 gene has been divided into six phylogenetic groups (GI–GVI) based on comprehensive sequence analysis of isolates spanning 1979–2016, further illustrating the complexity of CPV evolution [40]. It is also notable that the VP2 protein is under negative (purifying) selection overall, yet specific codons, particularly 324, 426, and 440, exhibit positive selection, indicating that adaptive evolution at these sites is driven by immune pressure or host receptor optimization [8, 40].

Host Range and Spillover Potential

The host range of CPV-2 extends well beyond domestic dogs, encompassing wild canids, felids, and even non-carnivore species. Serological surveys have documented widespread CPV-2 antibody prevalence in eastern coyotes, red foxes, and gray foxes in North America, highlighting the potential for bidirectional spillover between domestic and wildlife populations [3]. CPV-2 has been isolated from African lions in the Serengeti ecosystem, where infection dynamics in these wild felids follow those in the adjacent domestic dog population [24]. Similarly, CPV-2b has been confirmed in a serval in South Africa, and CPV-2c has caused fatal infections in Taiwanese pangolins (Manis pentadactyla pentadactyla), providing compelling evidence of cross-species transmission to non-carnivore hosts [9, 25, 32]. In 2020, the first documented spillover of CPV-2 to pigs was reported in South Dakota, USA, with genetic analysis suggesting a wildlife reservoir origin [4]. Additionally, CPV-2 DNA has been detected in dog ticks, raising the speculative possibility that arthropods may contribute to mechanical transmission [41]. These findings collectively demonstrate that CPV-2 is a multi-host pathogen with the capacity to infect a broad spectrum of mammalian species, necessitating a One Health approach to surveillance and control [3, 24].

Global Prevalence and Epidemiological Significance

The global burden of CPV-2 disease is immense, with up to 100% morbidity and 91% mortality reported in unvaccinated or inadequately vaccinated puppies [1]. Prevalence rates vary widely by region and population: in central Turkey, prevalence reached 86.27% between 2020 and 2022 [1]; in Ghana, antigen detection revealed 61.11% positive samples among clinically ill dogs [42]; in Australia, an estimated 20,000 cases occur annually, with a 41% euthanasia rate [26, 37]. The World Organisation for Animal Health (WOAH) recognizes CPV-2 as a notifiable pathogen due to its economic impact and potential for rapid spread. Risk factors include young age (especially puppies 6–16 weeks), lack of vaccination or incomplete vaccination series, high population density in shelters or kennels, and seasonal peaks during spring and early summer in temperate climates [19, 26, 29]. Socioeconomic disadvantage is among the strongest predictors of CPV-2 incidence, as access to preventive veterinary care is often constrained by cost [29]. The virus’s extreme environmental stability, resisting many common disinfectants and persisting for months to years on fomites and soil, further complicates control efforts [14, 36]. Successful eradication of CPV-2 is considered unlikely in the near future, owing to the combined challenges of maternal antibody interference with vaccination, the emergence of immune-evasive variants, and the existence of extensive wildlife reservoirs [5, 15].

Molecular Pathogenesis of Canine Parvovirus

The molecular pathogenesis of canine parvovirus type 2 (CPV-2) represents a paradigm of viral-host co-evolution, wherein a single-stranded DNA (ssDNA) virus with a genome of approximately 5,200 nucleotides orchestrates a cascade of cellular and systemic events culminating in severe, often fatal disease. Understanding this process at the molecular level is critical for developing therapeutic interventions, refining vaccine strategies, and predicting the emergence of novel variants with altered pathogenic potential. The virus, a member of the genus Protoparvovirus within the family Parvoviridae, exhibits a remarkable tropism for rapidly dividing cells, a characteristic that dictates its clinical and pathological signature [12, 14].

Viral Entry, Receptor Binding, and Cellular Tropism

The initial step in CPV-2 pathogenesis is the attachment of the viral capsid to the host cell surface. The primary determinant of cellular tropism is the capsid protein VP2, which constitutes the majority of the icosahedral capsid. CPV-2 utilizes the transferrin receptor (TfR) for entry into host cells [15]. The specificity of this interaction is a key molecular determinant of host range. The original CPV-2 emerged from feline panleukopenia virus (FPV) following a few critical amino acid substitutions in VP2 that enabled binding to the canine TfR [4, 15]. This host-switching event, which occurred in the late 1970s, was a seminal moment in viral pathogenesis, allowing a previously feline-adapted virus to cause a global pandemic in canids [4, 15].

The VP2 protein is not merely a structural scaffold; it is the primary interface for host interaction and the target of the host immune response. Mutations in VP2, particularly in the region encompassing residues 93 to 103 and the GH loop (residues 222-229), directly influence receptor binding affinity and antigenicity [15]. The three major antigenic variants, CPV-2a, CPV-2b, and CPV-2c, are defined by specific amino acid changes at residue 426 of VP2 (Asn in 2a, Asp in 2b, Glu in 2c) [16, 38]. These substitutions, while altering antigenic profiles, also fine-tune the interaction with the TfR, potentially influencing tissue tropism and virulence [27]. For instance, the CPV-2c variant (426Glu) has been associated with more severe clinical disease and a higher incidence of vaccine failure in some studies, though this remains a subject of active investigation [21, 51]. The molecular basis for this may lie in altered receptor binding kinetics or immune evasion, as residues near 426 are located within a major antigenic epitope [8, 52].

Replication Cycle and Cytopathic Effects

Following TfR-mediated endocytosis, the viral genome is released into the nucleus, where replication occurs. CPV-2 is a non-enveloped virus with a linear ssDNA genome. Its replication is absolutely dependent on the host cell's DNA replication machinery, which is only active during the S-phase of the cell cycle [14]. This explains the virus's strict tropism for mitotically active cells, such as intestinal crypt epithelial cells, bone marrow progenitor cells, and lymphoid cells. The non-structural protein NS1 is the master regulator of viral replication and a key mediator of cytotoxicity [10]. NS1 possesses helicase and nicking activities, essential for rolling-circle replication of the viral genome. More importantly, NS1 induces DNA damage, activates caspases, and triggers mitochondrial dysfunction, leading to apoptosis of the infected cell [10]. This NS1-mediated cytotoxicity is the primary driver of the pathological lesions seen in CPV-2 infection.

The replication cycle is rapid and highly efficient, leading to the destruction of the host cell within hours. In the intestinal crypts, this results in the necrosis of the proliferating epithelial cells, causing villous atrophy, crypt dilation, and loss of absorptive surface area [14, 51]. This loss of intestinal barrier integrity leads to the hallmark clinical signs of hemorrhagic diarrhea, vomiting, and protein-losing enteropathy. Concurrently, infection of lymphoid tissues (Peyer's patches, mesenteric lymph nodes, thymus, spleen) and bone marrow leads to profound lymphopenia and neutropenia, a critical feature of CPV-2 pathogenesis [44, 46]. The resulting immunosuppression predisposes the animal to secondary bacterial infections and sepsis, which is a major cause of mortality [46, 48].

Systemic Dissemination and Multi-Organ Involvement

Following initial replication in the oropharynx and lymphoid tissues, CPV-2 disseminates via the bloodstream (viremia) to target organs. The severity of disease is directly correlated with the extent of viral replication in these tissues. The virus infects and destroys hematopoietic progenitor cells in the bone marrow, leading to panleukopenia [14, 44]. The loss of neutrophils is particularly devastating, as these cells are the first line of defense against bacterial translocation from the damaged gut. The resulting sepsis is a common terminal event, characterized by systemic inflammatory response syndrome (SIRS) and multi-organ dysfunction [46, 50].

Acute kidney injury (AKI) is a frequent but often underdiagnosed complication of CPV-2 infection. The pathogenesis of AKI is multifactorial, involving severe dehydration, hypotension from fluid loss, and sepsis-induced renal hypoperfusion [50]. However, direct viral damage to renal tubular cells may also contribute. Studies using novel urinary biomarkers such as neutrophil gelatinase-associated lipocalin (uNGAL) and retinol-binding protein (uRBP) have demonstrated that tubular injury occurs even in the absence of elevated serum creatinine, indicating that AKI is more common than previously recognized [50]. This highlights the importance of monitoring renal function in CPV-2 patients, as subclinical AKI can significantly impact recovery.

Myocarditis, a less common but often fatal form of the disease, occurs primarily in very young puppies (neonates) infected in utero or shortly after birth [14, 51]. In these animals, the virus targets the rapidly dividing cardiomyocytes, causing extensive myocardial necrosis and inflammation. This can lead to acute heart failure and sudden death, or chronic myocardial fibrosis and long-term cardiac dysfunction in survivors.

Long-Term Sequelae and Chronic Disease

The molecular pathogenesis of CPV-2 extends beyond the acute phase of infection. Surviving animals are at a significantly increased risk of developing chronic gastrointestinal disease later in life [47]. A landmark study demonstrated that dogs surviving CPV-2 infection had a 5.33-fold higher odds of developing chronic gastroenteritis compared to matched controls [47]. The proposed mechanism involves a permanent disruption of the intestinal architecture and the gut-associated lymphoid tissue (GALT). The severe damage to the intestinal crypts during the acute infection may lead to incomplete regeneration, altered stem cell niches, and a persistent state of low-grade inflammation or dysbiosis. This "scarring" of the intestinal ecosystem can predispose the animal to chronic diarrhea, food intolerance, and inflammatory bowel disease (IBD)-like conditions [47]. This finding underscores that CPV-2 infection is not merely an acute, self-limiting disease but can have profound, lifelong consequences for the host.

Molecular Evolution and Emergence of Pathogenic Variants

The molecular pathogenesis of CPV-2 is inextricably linked to its rapid evolution. Despite being a DNA virus, CPV-2 has a substitution rate approaching that of RNA viruses, estimated at approximately 4.586 × 10⁻⁴ substitutions per site per year for the VP2 gene [39, 40]. This high rate of evolution is driven by a combination of factors, including a high mutation rate during replication, strong selective pressures from the host immune system, and the need to adapt to new hosts [15, 40].

The emergence of the three antigenic variants (2a, 2b, 2c) is a direct consequence of this evolutionary pressure. These variants have completely replaced the original CPV-2 and now circulate globally with varying prevalence [1, 2, 11]. Critically, the evolution is ongoing. New "Asian" CPV-2c strains, characterized by specific amino acid signatures such as VP2 A5G, F267Y, Y324I, and Q370R, are now spreading across Europe, Africa, and the Americas, displacing older variants [6, 17, 18, 22, 30]. These mutations are not neutral; they occur in antigenically critical regions of VP2, suggesting they confer a selective advantage, likely through enhanced immune evasion or altered receptor binding [1, 6, 8]. The Q370R mutation, for example, is located in a major antigenic site and may reduce the binding affinity of neutralizing antibodies elicited by current vaccines [6, 49]. This continuous antigenic drift poses a significant challenge to vaccine efficacy and is a major factor in the persistence of CPV-2 as a leading cause of puppy mortality worldwide [1, 5, 21].

Furthermore, the virus's ability to jump species is a testament to its adaptive potential. CPV-2 has been documented infecting a wide range of non-canine hosts, including cats, foxes, coyotes, pangolins, otters, servals, and even pigs [3, 9, 25, 32, 45, 53]. The spillover into pigs in South Dakota in 2020 [4] and the fatal infection of Taiwanese pangolins [9, 25] highlight the virus's capacity to exploit new ecological niches. The molecular basis for these cross-species transmissions often involves a small number of key mutations in VP2 that allow the virus to bind to the TfR of the new host species [15]. This ongoing evolution and host-switching behavior makes CPV-2 a model system for studying viral emergence and a pathogen of significant concern for both domestic animal and wildlife health, warranting continuous surveillance by organizations such as the World Organisation for Animal Health (WOAH).

Epidemiology and Strain Distribution of Canine Parvovirus

Global Emergence and Evolutionary Origins

The epidemiological landscape of canine parvovirus type 2 (CPV-2) represents one of the most remarkable examples of viral emergence and global dissemination in modern veterinary medicine. The virus first appeared as a pathogen of dogs in the late 1970s, originating from a spillover event involving a feline panleukopenia-like virus [4, 15]. This cross-species transmission event triggered a worldwide pandemic of acute enteritis and myocarditis among canids, fundamentally altering the infectious disease profile of domestic dogs globally. The original CPV-2 strain, however, was remarkably short-lived in its original form; within a few years of its emergence, the original antigenic type was completely supplanted by three antigenic variants, designated CPV-2a, CPV-2b, and CPV-2c, which continue to circulate and evolve in canine populations worldwide [1, 2, 5, 12].

The evolutionary success of CPV-2 is particularly striking given its genomic characteristics. Despite being a single-stranded DNA virus, CPV-2 exhibits a substitution rate approaching that of many RNA viruses, with estimates for the VP2 gene ranging from approximately 4.586 × 10⁻⁴ substitutions per site per year [39, 40]. This molecular evolutionary rate has facilitated the relatively rapid emergence of genetic and phenotypic variants, enabling the virus to adapt to new hosts and evade immune pressures. However, as Voorhees et al. [15] demonstrated through comprehensive full-genome and deep-sequencing analyses spanning 40 years of viral circulation, all CPV variants remain more than approximately 99% identical in nucleotide sequence, with fewer than 40 substitutions achieving fixation or widespread distribution during this period. Notably, most substitutions in the VP2 capsid protein gene are nonsynonymous, altering amino acid residues within or adjacent to receptor-binding footprints and antigenic regions, suggesting that natural selection has channeled much of CPV evolution [15].

Global Distribution and Shifting Dominance of Antigenic Variants

The distribution of CPV-2 antigenic variants across global canine populations has undergone substantial and dynamic shifts since the virus first emerged. Hao et al. [2] conducted a comprehensive analysis of all VP2 sequences available in the NCBI database from 1978 to 2022, revealing that CPV-2c exhibits a clear trend toward replacing CPV-2a as the dominant variant in Asia, South America, North America, and Africa. This global shift has profound implications for vaccine efficacy and disease control strategies, as different variants may exhibit differential antigenicity and virulence profiles.

In Asia, the epidemiological picture has been particularly dynamic. Chen et al. [7] analyzed 683 Chinese CPV-2 strains identified between 2014 and 2019, documenting that CPV-2c has gained an epidemiological advantage over the newer CPV-2a variant in China. This finding contrasts with earlier reports and suggests a significant epidemiological transition in the region. The CPV-2c variant has been frequently associated with immune failure in adult dogs, raising concerns about the adequacy of current vaccination protocols [7]. In Vietnam, Hoang et al. [23] conducted a comprehensive genotyping survey from November 2016 to February 2018, examining 260 isolates from northern, central, and southern regions. Their results demonstrated an overwhelming predominance of CPV-2c, which accounted for 96.54% of isolates (251/260), with CPV-2a representing only 2.31% (6/260) and CPV-2b entirely absent. This pattern was consistent across all three geographic regions of Vietnam [23]. Similarly, in Thailand, Inthong et al. [54] documented a dramatic shift in circulating variants between 2010 and 2018. In 2010, all 60 positive samples were classified as new CPV-2a or new CPV-2b; however, by 2018, 19 of 25 positive samples (76%) were CPV-2c, with only 5 new CPV-2a and no CPV-2b detected, alongside one feline panleukopenia virus (FPV) identified in a diarrheic dog [54].

The emergence of CPV-2c in Taiwan has been particularly well-documented. Chiang et al. [43] first identified CPV-2c in Taiwan in 2015, characterizing it as a novel variant distinct from previously circulating strains. Among 88 isolates obtained from January 2014 to April 2016, CPV-2c was the dominant variant (54.6%), followed by CPV-2b (26.1%) and CPV-2a (19.3%). Phylogenetic analysis demonstrated that these Taiwanese CPV-2c variants clustered with Chinese CPV-2c strains, suggesting a common evolutionary origin and potential cross-strait transmission [43]. Subsequent phylodynamic analysis by Lin et al. [39] estimated the time to the most recent common ancestor for Taiwanese CPV-2c isolates at approximately 2011, with the phylogenetic clade beginning to branch off around 2010. The evolutionary rate of CPV-2c was estimated at 4.586 × 10⁻⁴ substitutions per site per year, and demographic reconstruction using Bayesian skyline plots indicated that the effective population size of CPV-2c increased until 2006 before slowly declining until 2011 [39].

In South Korea, Moon et al. [18] reported the first documented cases of CPV-2c infection in two dogs with severe diarrhea. Complete open reading frame sequencing revealed that these Korean CPV-2c strains shared 99.48% reciprocal nucleotide sequence identity and had the highest nucleotide identity (99.77%–99.34%) with Asian CPV strains isolated in China, Italy (from a dog imported from Thailand), and Vietnam between 2013 and 2017. Phylogenetic analysis demonstrated that Korean CPV-2c strains clustered closely with Asian CPV strains, separately from isolates from Europe, South America, and North America [18].

The Asian CPV-2c Lineage: A Distinct Epidemiological Entity

One of the most significant findings in recent CPV-2 epidemiology has been the emergence and global dissemination of a distinct Asian lineage of CPV-2c, characterized by specific amino acid signatures in the VP2 protein. This lineage, first identified in Asia, carries unique mutations including Ala5Gly (A5G), Phe267Tyr (F267Y), Tyr324Ile (Y324I), and Gln370Arg (Q370R) [1, 2, 6, 7, 17, 49]. Hao et al. [2] noted that CPV-2c strains prevalent in most regions of Asia carry two special mutations in VP2, A5G and Q370R, which have become dominant mutations with spillover already occurring beyond the Asian continent.

The spread of this Asian CPV-2c lineage beyond its geographic origin has been documented in multiple European countries, raising concerns about intercontinental viral dissemination. Balboni et al. [6] characterized CPV-2c strains from ten dogs with acute gastroenteritis in Romania, identifying that all ten viruses belonged to the CPV-2c type with identical VP2 sequences characterized by distinctive amino acid residues: 5Gly, 267Tyr, 324Ile, and 370Arg. These signatures had previously been reported in CPV-2c strains widespread in Asia and occasionally detected in Italy and Nigeria. The authors emphasized that since CPV-2c with these VP2 amino acid residues were never reported before 2013, this virus is progressively expanding its spread in the world dog population [6]. Similarly, Mira et al. [17] documented the circulation of CPV-2c mutants of Asian origin in southern Italy, observing the co-circulation of two different but related CPV-2c strains with amino acid changes characteristic of Asian CPV strains, including NS1: 60V, 544F, 545F, 630P; NS2: 60V, 151N, 152V; and VP2: 5A/G, 267Y, 297A, 324I, 370R. Phylogenetic analyses confirmed the relationship with Asian CPV-2c strains [17].

The introduction of these Asian strains into Europe has been directly linked to dog importation. Mira et al. [30] provided definitive evidence of this mechanism by genomically characterizing a CPV strain collected from a dog recently imported to Italy from Thailand. The virus was detected in all tissue samples collected, and genetic analysis revealed a CPV-2c strain with genetic signatures typical of Asian strains, including amino acid changes never previously observed in European CPV-2c strains. Full-genome analysis confirmed that the strain clustered with Asian viruses, providing compelling evidence that the movement of dogs facilitates the global spread of viral variants [30].

Strain Distribution in Europe: Complexity and Regional Variation

The epidemiological situation in Europe is characterized by substantial complexity and regional variation in the distribution of CPV-2 variants. Battilani et al. [28] conducted a comprehensive longitudinal study of CPV-2 in Italy from 1994 to 2017, analyzing VP2 gene sequences from 123 dogs with clinical gastroenteritis. Their results revealed that all three antigenic types circulated in Italy, with CPV-2a being the prominent genotype, followed by CPV-2c and CPV-2b, but with notable regional differences and significant fluctuations over time. Sequence analysis identified 67 nucleotide sequence types and 21 amino acid sequence types, with CPV-2a exhibiting the highest genetic variability (61.2% of nucleotide sequence types) while CPV-2c was characterized by notable stability with a predominant amino acid profile throughout the sampling period. An important finding was the re-emergence of CPV-2b in recent years, showing a new and distinctive amino acid profile of the VP2 protein [28].

Tucciarone et al. [34] further elaborated on Italian CPV heterogeneity by analyzing 100 geographically annotated samples collected from 2008 to 2015. Their results confirmed that CPV-2a was the most prevalent variant (60%), but also demonstrated that CPV appeared widely distributed across Italy without any regional or temporal clustering, indicating extensive and uncontrolled within-country viral spreading. When contextualized within the international scenario, the analysis revealed remarkable genetic heterogeneity of circulating strains and their broad distribution, with frequent viral exchange among countries over both short and long distances [34].

In Sardinia, Giudici et al. [56] analyzed 81 animals and found that all antigenic CPV-2 types were circulating, with CPV-2b appearing to be the most widespread variant, followed by CPV-2a. Notably, 12 CPV-2b strains displayed further amino acid substitutions and formed a separate cluster in the phylogenetic tree, indicating regional genetic variation on this Mediterranean island [56].

The situation in Turkey reflects the broader Eurasian epidemiological dynamics. Temizkan and Temizkan [1] conducted a comprehensive study of CPV in Turkey using next-generation sequencing and Sanger sequencing on 80 samples collected between 2020 and 2022. They found that CPV-2b had become the most frequent genotype in the region, while the incidence of CPV-2c was predicted to increase gradually in coming years. The CPV-2 variants circulating in Turkey formed their own cluster while being closely related to Egyptian variants, suggesting regional epidemiological connections. Substantial amino acid changes were detected in antigenically important regions of the VP2 gene, and the prevalence of CPV in central Turkey was alarmingly high at 86.27% [1]. Polat et al. [55] had previously documented the co-existence of CPV-2a, 2b, and 2c variants in southeast Anatolia, with CPV-2b being the most prevalent and the CPV-2c sample phylogenetically related to Chinese and Indonesian strains.

Strain Distribution in Africa and Latin America

The epidemiological picture in Africa has been less comprehensively characterized, but available data reveal important patterns. Ogbu et al. [22] conducted the first CPV molecular characterization including all encoding gene sequences from the African continent, analyzing 59 positive samples from Nigeria. Their results revealed a striking predominance of CPV-2c, which accounted for 91.5% of isolates compared to only 8.5% for CPV-2a. VP2 gene sequences showed divergence from strains analyzed in 2010 in Nigeria and demonstrated a closer connection with CPV strains of Asian origin, suggesting potential epidemiological linkages between Africa and Asia [22].

In South America, Grecco et al. [33] conducted a comprehensive phylodynamic analysis of CPV populations, generating genomic sequences of 63 strains from South America and Europe. Their findings revealed that all obtained strains belonged to the CPV-2a lineage and associated with global strains in four monophyletic groups or clades. European and South American strains formed the widely distributed Eur-I clade, which emerged in Southern Europe during 1990–1998 before spreading to South America in the early 2000s. The Asia-I clade included strains from Asia and Uruguay, originating in Asia during the late 1980s and spreading to South America during 2009–2010. The Eur-II clade comprised strains from Italy, Brazil, and Ecuador, appearing in South America as a consequence of early introduction from Italy to Ecuador in the mid-1980s. Importantly, some strains from Argentina, Uruguay, and Brazil constituted an exclusive South American clade (SA-I) that emerged in Argentina in the 1990s. These findings indicate that the current epidemiological scenario in South America is a consequence of inter- and intracontinental migrations of strains with different geographic and temporal origins, setting the conditions for competition and local differentiation of CPV populations [33].

In Chile, Alexis et al. [8] performed molecular characterization of the VP2 gene from 18 positive samples collected in central Chile. Their analysis revealed a higher rate of CPV-2c-positive patients compared to CPV-2b, with amino acid characterization indicating mutations in regions of highest antigenicity. CPV-2b exhibited mutations at positions 297 and 324, while CPV-2c showed mutations at position 440, along with other previously undocumented mutations. Selection pressure analysis demonstrated that the VP2 gene is under negative selection overall, but positive selection point sites were identified for both CPV-2c (324, 426, and 440) and CPV-2b (297 and 324), at sites associated with immune evasion via antigenic drift [8].

Interspecies Transmission and Wildlife Spillover

The host range of CPV-2 extends well beyond domestic dogs, with documented infections in numerous wildlife species across multiple continents. This spillover has significant implications for wildlife conservation and the maintenance of CPV in sylvatic cycles. Kimpston et al. [3] screened serum from free-ranging eastern coyotes (Canis latrans), red foxes (Vulpes vulpes), and gray foxes (Urocyon cinereoargenteus) from Pennsylvania, USA, for antibodies to CPV. Antibodies were detected in 45.5% of coyotes, 52.4% of red foxes, and 68.8% of gray foxes, demonstrating significant wildlife exposure in a northeastern state. As wildlife species continue to urbanize, the probability of spillover between domestic animals and wildlife will increase, warranting ongoing surveillance [3].

The spillover of CP

Clinical Manifestations and Pathophysiology of Canine Parvovirus

Canine parvovirus type 2 (CPV-2) induces a spectrum of clinical disease that ranges from subclinical infection to a rapidly fatal syndrome characterized by profound gastroenteritis, immunosuppression, and multi-organ dysfunction. The clinical expression of CPV-2 infection is fundamentally a consequence of the virus’s strict tropism for rapidly dividing cells, a biological imperative driven by its dependence on host-cell DNA polymerase and replication machinery present during the S-phase of the cell cycle [14]. This tropism dictates the primary targets: intestinal crypt epithelium, bone marrow hematopoietic precursors, lymphoid tissues, and, in neonatal animals, myocardial cells. The ensuing pathophysiological cascade involves direct viral cytolysis, disruption of the intestinal barrier, severe immunosuppression, systemic inflammatory response, and secondary complications such as sepsis and acute kidney injury. A comprehensive understanding of these interconnected processes is essential for rational clinical management and prognostication.

Clinical Forms and Spectrum of Disease

CPV-2 infection typically manifests in two classical clinical forms: the enteric form and the myocardial form, with the former being overwhelmingly more common in contemporary practice [14]. The enteric form is most frequently observed in puppies between 6 and 20 weeks of age, although older unvaccinated or inadequately vaccinated dogs remain susceptible [5, 14]. The incubation period following oronasal exposure is typically 3 to 7 days [14]. The prodromal phase is often subtle, with lethargy, anorexia, and a mild fever preceding the onset of gastrointestinal signs. Within 24 to 48 hours, the hallmark clinical signs emerge: vomiting, often bilious and intractable, followed by diarrhea that rapidly progresses from mucoid to hemorrhagic and foul-smelling [14, 44]. Profuse bloody diarrhea is reported in a substantial proportion of cases, with one comparative study documenting its occurrence in 90.4% of affected dogs [59]. The combination of vomiting and diarrhea leads to rapid and severe dehydration, electrolyte imbalances (notably hypokalemia and hyponatremia), and metabolic acidosis. Fever, often exceeding 39.5°C, is common during the early phase due to systemic inflammation and cytokine release, but hypothermia may supervene in terminal stages or in cases of overwhelming sepsis [44]. Abdominal pain, as evidenced by a hunched posture or reluctance to move, is frequently noted. Lymphopenia, a pathognomonic hematologic finding, results from viral destruction of lymphocytes in lymphoid tissues and bone marrow [14, 44]. Leucopenia, involving both neutrophils and lymphocytes, is a critical indicator of disease severity and a negative prognostic marker.

The myocardial form, historically described in the late 1970s shortly after the emergence of CPV-2, is now rarely encountered due to widespread maternal antibody protection in very young puppies [4, 14]. This form occurs in puppies infected in utero or within the first few weeks of life, before the heart has completed its cellular differentiation. The virus replicates in cardiomyocytes, leading to acute necrotizing myocarditis, cardiac arrhythmias, and sudden death, often with minimal antecedent gastrointestinal signs [14]. Survivors may develop chronic myocardial fibrosis and congestive heart failure later in life. While less common today, the myocardial form serves as a stark illustration of CPV-2’s capacity for severe, tissue-specific pathology in the absence of protective immunity.

Pathophysiology of Gastrointestinal Disease

The gastrointestinal tract is the primary site of CPV-2-induced pathology and the source of the most clinically devastating manifestations. Following oronasal exposure, the virus undergoes primary replication in the oropharyngeal lymphoid tissues (tonsils and retropharyngeal lymph nodes) [14]. A cell-associated viremia then disseminates the virus to its principal target organs, including the intestinal crypts, bone marrow, and lymphoid follicles [14].

The pathogenesis of enteritis centers on the infection and destruction of intestinal crypt epithelial cells. These cells are among the most rapidly dividing in the body, making them exquisitely susceptible to CPV-2 replication. Viral entry into crypt cells is mediated by the transferrin receptor (TfR), an interaction that dictates host range and tissue tropism [15, 52]. Within the crypts, viral replication culminates in cellular necrosis and lysis, leading to crypt necrosis and collapse[14, 48]. This loss of crypt epithelium disrupts the regeneration of absorptive villous enterocytes, which undergo a natural turnover from the crypt base. Consequently, the intestinal villi become blunted, fused, and denuded, resulting in a dramatic loss of absorptive surface area [14, 48, 51]. The functional consequences are profound: maldigestion, malabsorption, and osmotic diarrhea. The damaged intestinal barrier allows for the leakage of fluid, electrolytes, and proteins into the intestinal lumen, compounding the diarrhea and dehydration. The presence of blood in the stool reflects severe mucosal hemorrhage from the damaged and ulcerated lamina propria, particularly when the crypt necrosis extends deeper into the submucosa [51].

The disruption of the intestinal barrier is a pivotal event in the pathophysiology of severe CPV disease. The loss of epithelial integrity permits the translocation of luminal bacteria and their products (e.g., lipopolysaccharide, LPS) into the systemic circulation [46]. This bacterial translocation is a primary driver of the septic and systemic inflammatory response syndrome (SIRS) that characterizes severe CPV infection. Alves et al. [46] demonstrated that CPV enteritis serves as a predisposing condition for sepsis, and that the presence of SIRS criteria, particularly those reflecting altered capillary refill time or mucous membrane color, is significantly associated with mortality. The resulting systemic inflammation is characterized by a cytokine storm, activation of the complement and coagulation cascades, and endothelial damage, which can progress to multi-organ dysfunction. The coagulation system is particularly affected; Franzo et al. [27] identified a strong phylogenetic signal linking specific CPV clades to alterations in the coagulation profile, underscoring that viral genetics may influence the severity of this systemic complication.

Immunosuppression and Hematologic Effects

In parallel with its gastrointestinal effects, CPV-2 exerts a profound and direct immunosuppressive effect through its infection of lymphoid and hematopoietic tissues. The virus infects and lyses rapidly dividing lymphocyte precursors in the bone marrow, thymus, spleen, and lymph nodes [14]. This leads to severe lymphopenia, which is detectable as early as 3–5 days post-infection and often precedes the onset of clinical signs [44]. Concurrently, infection of granulocyte-macrophage progenitors in the bone marrow results in neutropenia[14]. The combination of lymphopenia and neutropenia constitutes a state of functional immunosuppression that leaves the host vulnerable to secondary bacterial infections, which are a leading cause of morbidity and mortality.

The degree of lymphopenia has been correlated with disease severity. In the experimental challenge study by Larson et al. [44], CPV monoclonal antibody-treated dogs exhibited significantly less severe lymphopenia compared to controls, indicating that reduction of viral load can attenuate this hematologic insult. Furthermore, the depletion of lymphocytes extends to the gut-associated lymphoid tissue (GALT), including Peyer’s patches, which exacerbates the local immune dysfunction and contributes to bacterial translocation [48]. The immunosuppressive phase is transient if the animal survives, with lymphocyte counts typically beginning to recover after 5–7 days, coinciding with the clearance of viremia [19, 44].

Systemic and Organ-Specific Complications

Beyond the gastrointestinal tract and immune system, CPV-2 infection can trigger a cascade of systemic complications that significantly worsen prognosis. Acute kidney injury (AKI) is a frequently underdiagnosed complication. Berg et al. [50] demonstrated that dogs with CPV infection had significantly elevated urinary biomarkers of both glomerular (urinary IgG, C-reactive protein) and tubular (urinary retinol-binding protein, neutrophil gelatinase-associated lipocalin) injury, despite having normal or low serum creatinine and urea. This indicates that structural kidney damage occurs early in the disease due to a combination of severe dehydration, hypovolemia, hypotension, and sepsis-induced inflammation, but is masked by the concurrent muscle wasting and decreased creatinine production characteristic of critical illness [50]. The detection of AKI using novel biomarkers highlights a pathophysiological process that was previously underappreciated and may contribute to morbidity in survivors.

Cardiopulmonary complications can also occur. While the myocardial form is rare, adult dogs can experience myocarditis and arrhythmias secondary to systemic inflammation and electrolyte disturbances. Pulmonary edema was noted in 7 of 24 CPV-2c cases in one study, likely due to a combination of increased vascular permeability from SIRS and aggressive fluid therapy [51]. Neurologic signs, including convulsions, have been sporadically reported, possibly due to cerebral edema, electrolyte imbalances, or rarely, direct viral invasion of the central nervous system [51].

Long-term sequelae are an emerging concern. Kilian et al. [47] conducted a landmark follow-up study demonstrating that dogs surviving CPV infection had a significantly higher risk (odds ratio = 5.33) of developing chronic gastrointestinal disease later in life compared to matched controls. The chronic enteropathy likely results from dysbiosis, altered intestinal architecture, and a persistent inflammatory state triggered by the initial severe crypt damage and disruption of the mucosal immune system [47, 58]. This finding underscores that CPV infection is not merely an acute disease but can have lifelong health implications for affected animals. Coinfections with other enteric pathogens, such as canine circovirus, canine distemper virus, canine coronavirus, and Neospora caninum, are common and can exacerbate the severity of clinical signs by compounding the immunological and epithelial damage [48, 57].

Influence of Viral Variants on Clinical Severity

The genetic heterogeneity of CPV-2, particularly among the VP2-based antigenic variants (CPV-2a, -2b, -2c), has raised questions about differential virulence. A seminal study by Franzo et al. [27] provided the first robust evidence that viral phylogeny is associated with disease severity. Using statistical modeling, the authors demonstrated a significant phylogenetic signal for parameters such as white blood cell count and neutrophil count, suggesting that virulence is an inherited trait that clusters within specific CPV lineages, rather than being strictly tied to the classical antigenic classification [27]. This finding implies that emergent strains, such as the Asian-origin CPV-2c mutants now spreading globally (featuring VP2 mutations A5G, F267Y, Y324I, and Q370R), may possess enhanced virulence or altered tissue tropism [6, 17, 18, 30]. Indeed, CPV-2c has been associated with more severe disease in some studies and is increasingly linked to vaccine failures [5, 21, 39]. The pandemic spread of these Asian-lineage CPV-2c strains across continents, as documented in Europe [17, 30], South America [8, 33], and Africa [22], highlights the clinical importance of ongoing viral evolution. The immune evasion potential conferred by these mutations, particularly those in antigenic regions of the VP2 protein, can lead to infection in vaccinated animals and more severe clinical presentations due to reduced neutralizing antibody efficacy [5, 8, 21].

Summary of Pathophysiological Cascade

In synthesis, the clinical manifestations of CPV-2 infection are the integrated result of a defined pathophysiological cascade: viral entry via the TfR on rapidly dividing cells → lytic infection of intestinal crypt epithelium leading to villous atrophy and barrier disruption → direct immunosuppression through lymphoid and myeloid cell destruction → bacterial translocation and endotoxemia → SIRS and septic shock → multi-organ dysfunction (AKI, cardiac, pulmonary) → and in survivors, potential for chronic enteropathy. The severity of this cascade is modulated by host factors (age, immune status, breed, comorbidities) and viral factors (genetic lineage, specific mutations influencing replication rate or immune evasion). A recognition of this detailed pathophysiology is crucial for clinicians, as it directly informs therapeutic strategies: aggressive fluid resuscitation, antimicrobial therapy to combat translocation, nutritional support, and novel adjunctive therapies such as fecal microbiota transplantation, which has been shown to accelerate recovery of gastrointestinal function [58], and monoclonal antibody therapy, which can neutralize viremia and attenuate all downstream clinical consequences when administered early [44].

Diagnostics and Genomic Surveillance of Canine Parvovirus

The accurate diagnosis and continuous genomic surveillance of canine parvovirus type 2 (CPV-2) are cornerstones of effective disease management, outbreak control, and vaccine strategy optimization. Given the virus's remarkable evolutionary rate, approaching that of many RNA viruses despite its single-stranded DNA genome [15, 40], diagnostic methodologies must be both sensitive and specific to detect emerging variants, while surveillance frameworks must capture the nuanced dynamics of viral spread across geographically distinct populations and host species. The World Organisation for Animal Health (WOAH) recognizes CPV-2 as a pathogen of significant economic and welfare concern, underscoring the need for standardized, validated diagnostic protocols that can operate effectively in both high-resource reference laboratories and resource-limited field settings.

Advanced Molecular Diagnostics and Point-of-Care Innovations

Traditional diagnostic approaches, primarily immunochromatographic antigen tests (ICTs), have long served as frontline tools in veterinary practice due to their rapid turnaround time and ease of use. However, mounting evidence reveals critical limitations, particularly in the detection of CPV-2c variants. A study comparing antigen tests, conventional PCR, and quantitative PCR (qPCR) across vaccinated and unvaccinated dogs found that while ICTs detected CPV in 73.2% of unvaccinated diseased dogs, their sensitivity plummeted to 41.2% in vaccinated dogs exhibiting clinical signs [21]. Crucially, 82.75% of these infections were caused by CPV-2c, and the antigen test failed to identify a substantial proportion of these cases, likely due to lower viral shedding in vaccinated animals or altered capsid epitope presentation [21]. This diagnostic blind spot is alarming, as it implies that reliance on antigen testing alone may lead to false negatives, delayed treatment, and continued environmental contamination.

In response to these challenges, molecular diagnostics have become the gold standard for CPV detection and typing. Conventional and real-time PCR assays targeting the VP2 gene offer exquisite sensitivity and the ability to differentiate between antigenic variants (CPV-2a, 2b, and 2c) based on critical residues at position 426 [38]. Multiplex TaqMan real-time PCR assays have been developed to simultaneously detect and discriminate all four antigenic types (original CPV-2, 2a, 2b, and 2c) with detection limits as low as 10¹ genome copies per reaction for most variants, and 10² for CPV-2c [62]. Such assays, when validated against DNA sequencing, demonstrate 100% agreement, providing robust capacity for both clinical diagnosis and epidemiological surveillance [31, 62]. High-resolution melting (HRM) analysis represents another rapid, cost-effective approach, enabling the simultaneous detection and differentiation of CPV and feline panleukopenia virus (FPV) in a single PCR reaction by exploiting a single nucleotide polymorphism at position 4408, achieving a detection limit of 4.2 genome copies [31].

The need for field-deployable, equipment-free diagnostics has driven the development of isothermal amplification technologies. Recombinase polymerase amplification (RPA) assays, for instance, can amplify CPV-2 DNA at a constant temperature of 38°C within 4–12 minutes, achieving analytical sensitivity equivalent to real-time PCR (10¹ copies per reaction) when combined with an exo probe for real-time fluorescence detection [64]. An even more accessible variant, lateral flow strip RPA (LFS RPA), requires only body heat (from a closed fist) for a 15-minute amplification, with results visible to the naked eye on a lateral flow strip within five minutes [63]. When tested against clinical samples, this assay detected CPV-2 DNA in 76.7% of cases, matching the performance of real-time PCR and significantly outperforming the SNAP antigen test (48.3%) [63]. Such innovations are transformative for cage-side diagnosis in shelters, rural clinics, and regions lacking cold-chain infrastructure.

At the frontier of diagnostic sensitivity, CRISPR-Cas13a-based nanosystems have been developed for attomolar detection of CPV-2. This approach couples recombinase polymerase amplification with Cas13a-mediated collateral cleavage of a fluorescent reporter, enabling detection of viral RNA copies with extraordinary precision within 30 minutes [61]. While still in the experimental phase, this technology offers the potential for ultra-sensitive, specific, and rapid detection that could revolutionize early outbreak identification and environmental surveillance.

Genomic Surveillance: Unraveling Global and Local Evolutionary Dynamics

Genomic surveillance of CPV-2 has moved far beyond simple variant typing to encompass whole-genome sequencing, phylodynamic analysis, and deep-sequencing of intrahost viral populations. The rationale is clear: CPV-2's substitution rate, estimated at approximately 4.586 × 10⁻⁴ substitutions per site per year for the VP2 gene [39], coupled with its global dissemination, has generated a complex tapestry of genetic lineages whose biological properties, including virulence, antigenicity, and host range, may differ substantially.

Whole-genome sequencing has revealed that the classification system based on a single amino acid (residue 426) to define antigenic variants (2a, 2b, 2c) is insufficient to capture true phylogenetic relationships [33]. Indeed, strains classified as CPV-2a from different continents often cluster in distinct clades with unique evolutionary histories. Phylodynamic analyses of South American CPV-2a strains, for example, identified at least four monophyletic clades (Eur-I, Eur-II, Asia-I, and SA-I) arising from multiple intercontinental introductions between the 1980s and 2000s, followed by local differentiation [33]. The Eur-I clade, which emerged in Southern Europe and later spread to South America in the early 2000s, correlates with a significant rise in the effective population size of CPV in both regions [33]. These findings underscore the necessity of whole-genome resolution to trace the origin and spread of new variants robustly.

Deep-sequencing of intrahost viral populations has provided critical insights into the evolutionary constraints acting on CPV-2. Contrary to the expectation that rapid host jumping and sustained transmission would generate high intrahost diversity, analysis of archival clinical samples from dogs and other hosts (1978–2018) revealed remarkably few subconsensus single nucleotide variants above 0.5% frequency [15]. This limited intrahost diversity suggests that CPV-2's successful host adaptation does not rely on a standing pool of genetic variation but rather on a low mutation rate, functional pleiotropy, and/or the absence of selective challenges since its initial emergence [15]. Experimental passages further demonstrate that rapid receptor-driven adaptation can occur without substantial preexisting genetic heterogeneity, a finding with profound implications for understanding viral emergence.

Globally, genomic surveillance has documented a progressive replacement of CPV-2a by CPV-2c in multiple continents, including Asia, South America, North America, and Africa [2, 7, 22, 23]. In China, for instance, CPV-2c has gained an epidemiological advantage over new CPV-2a, with VP2 protein sequence analysis revealing a suite of amino acid substitutions, including Ala5Gly, Phe267Tyr, Tyr324Ile, Gln370Arg, and Thr440Ala, that are increasingly fixed in circulating strains [7, 60]. Notably, the CPV-2c variants prevalent in Asia carry a specific combination of mutations (A5G and Q370R) that have become dominant and are now spilling over into other regions [2]. The detection of Asian-like CPV-2c strains in Europe, first identified in a dog imported from Thailand to Italy, and subsequently found in southern Italy, Romania, and Nigeria, confirms that dog movement and trade are potent drivers of intercontinental viral spread [6, 17, 22, 30]. These Asian-origin strains are characterized by distinctive VP2 residues (5Gly, 267Tyr, 324Ile, 370Arg) and non-structural protein markers (NS1: 60Val, 544Phe, 545Phe, 630Pro) that were previously unreported in European isolates [6, 17, 30].

The association between CPV phylogeny and disease severity is a burgeoning area of inquiry. A study analyzing 34 CPV-infected dogs found a significant phylogenetic signal for hematological parameters such as neutrophil count and white blood cell count, suggesting that viral virulence is an inherited trait linked to specific clades rather than to the canonical antigenic variant classification [27]. This finding has profound implications for clinical prognosis and vaccine design, as it implies that not all CPV-2c strains are equivalent in pathogenic potential, and that continuous monitoring of emergent lineages is essential.

Surveillance in Wildlife and Non-Traditional Hosts

The host range of CPV-2 has expanded far beyond domestic dogs, with genomic surveillance documenting spillover into wildlife and even non-carnivore species. Serosurveys in Pennsylvania revealed that 45.5% of eastern coyotes, 52.4% of red foxes, and 68.8% of gray foxes harbored antibodies against CPV, indicating widespread environmental exposure and potential wildlife reservoirs [3]. Fatal CPV-2c infections have been documented in Taiwanese pangolins (Manis pentadactyla pentadactyla), with VP2 gene sequences showing 100% identity to strains circulating in domestic dogs from Singapore, confirming direct spillover from canids [9, 25]. Similarly, CPV-2b was detected in a serval (Leptailurus serval) in South Africa, with phylogenetic analysis linking the isolate to Argentinean and South African dog strains [32]. Even more remarkably, CPV-2 has been identified in pigs in South Dakota, USA, with genetic analysis suggesting spillover from wildlife [4], and in a river otter (Lontra longicaudis) in Brazil, where immunohistochemistry confirmed parvovirus infection alongside parasitism by Dioctophyma renale [53].

These spillover events highlight the critical role of genomic surveillance in a One Health framework. The detection of CPV in ticks (Rhipicephalus sanguineus) from Palestine raises the provocative hypothesis that ticks may serve as mechanical vectors, potentially contributing to environmental persistence and transmission [41]. WOAH and the FAO emphasize that surveillance in wildlife sentinel populations is essential for early warning of emerging variants that could threaten domestic animal health. The emergence of Asian-derived CPV-2c in regions previously dominated by European or American lineages, and its detection in multiple host species, underscores the urgency of maintaining robust, globally coordinated surveillance networks that integrate diagnostic data with genomic sequencing.

Treatment Strategies and Monoclonal Antibody Therapy for Canine Parvovirus

The clinical management of canine parvovirus (CPV-2) enteritis has historically been a domain of intensive supportive care, aimed at countering the profound pathophysiological consequences of viral enteropathy, immunosuppression, and secondary sepsis. However, the therapeutic landscape is undergoing a paradigm shift with the advent of targeted biologic therapies, most notably monoclonal antibodies. This section provides an exhaustive analysis of the evolution of treatment strategies, from foundational intensive care protocols to groundbreaking immunotherapeutic interventions, while integrating the complex interplay of viral evolution, host-pathogen dynamics, and clinical epidemiology that informs modern therapeutic decision-making.

Standard of Care: Intensive Supportive Management and Its Limitations

The cornerstone of CPV-2 treatment for decades has been aggressive supportive care, designed to mitigate the effects of severe gastroenteritis, profound dehydration, protein-losing enteropathy, and systemic inflammatory response syndrome (SIRS). This regimen typically includes intravenous fluid therapy with balanced crystalloids supplemented with potassium and dextrose, antiemetics (e.g., maropitant, ondansetron), broad-spectrum parenteral antimicrobials (e.g., ampicillin-sulbactam combined with enrofloxacin or metronidazole) to address bacterial translocation from the damaged intestinal barrier, and nutritional support often provided via nasoesophageal tubes or parenteral routes [14, 19, 46]. The physiological rationale is sound: CPV-2 targets rapidly dividing cells, causing crypt epithelial necrosis in the small intestine, lymphoid depletion in Peyer’s patches, and bone marrow suppression, leading to leukopenia and profound immunodeficiency [12, 14]. This creates a permissive environment for Gram-negative and anaerobic bacterial translocation, which drives the sepsis and SIRS that are the primary causes of mortality [46].

The efficacy of this supportive approach is demonstrated by data from high-volume shelter medicine programs. A landmark retrospective analysis of 5,127 CPV-infected dogs treated at Austin Pets Alive! over 11.5 years reported an overall survival rate of 86.6% [19]. Crucially, the probability of survival increased dramatically to 96.7% after the first five days of care, with 80% of fatalities occurring within this initial critical window [19]. This underscores that the disease is most lethal during the acute phase of viremia and intestinal barrier failure, after which surviving dogs mount an adaptive immune response and begin epithelial regeneration. The study also identified that low-body-weight animals and male dogs were at significantly higher risk for mortality, while age was not a statistically significant factor in this model [19]. This suggests that metabolic reserve and perhaps sex-linked immunological factors influence outcomes. Despite these successes, standard therapy is far from perfect; it is resource-intensive, requires hospitalization for a median of seven days, and incurs substantial financial costs, which in Australia were reported at a median of $A1,500 per case, with treatment costs strongly correlating with euthanasia rates in socioeconomically disadvantaged regions [29, 37]. Furthermore, even successful survivors are at significant risk for long-term gastrointestinal sequelae; a controlled study demonstrated that dogs surviving CPV infection have a 5.33-fold increased odds of developing chronic gastrointestinal disease later in life, likely due to persistent dysbiosis, altered intestinal barrier function, or chronic low-grade inflammation [47].

Monoclonal Antibody Therapy: A Targeted Immunotherapeutic Revolution

The most transformative recent advance in CPV therapeutics is the development and licensure of a canine parvovirus monoclonal antibody (CPMA). This represents a departure from polyclonal antisera or passive immunity derived from hyperimmune plasma, offering a standardized, potent, and mechanistically defined intervention. The pivotal study by Larson et al. (2024) provides compelling evidence for CPMA efficacy in a controlled experimental challenge model [44]. In this study, purpose-bred 8-week-old Beagle dogs were challenged intranasally with a virulent CPV-2b strain. On Day 4 post-challenge, at the onset of fecal viral shedding (a clinically relevant timepoint for diagnosis), the treated group received a single intravenous dose of CPMA (0.2 mL/kg) while controls received saline. No other supportive treatments were administered, isolating the effect of the monoclonal antibody.

The results were dramatic: mortality was prevented in 100% (21/21) of CPMA-treated dogs compared to 57% (4/7) mortality in the control group (P = 0.0017) [44]. Beyond survival, the treated dogs experienced significantly less severe and shorter durations of diarrhea, fever, vomiting, fecal viral shedding, and lymphopenia [44]. Virologically, this is consistent with the mechanism of action: the monoclonal antibody binds directly to the viral capsid (VP2 protein), likely neutralizing virus particles in the bloodstream and interstitial spaces before they can infect target cells in the intestinal crypts and bone marrow. The rapid clearance of viremia reduces the viral burden on the host’s lymphoid system, preserving some degree of immune function and mitigating the profound leukopenia that typically characterizes severe disease. Importantly, the study demonstrated that CPMA administration did not interfere with the development of the host’s own adaptive immunity; both treated and surviving control dogs mounted comparable immunoglobulin M (IgM) responses [44]. This is a critical safety finding, as it confirms that passive immunotherapy does not block the endogenous humoral response necessary for long-term protection and clearance of the virus from tissues.

The clinical relevance of this finding cannot be overstated. For the first time, a single-dose, pathogen-specific intervention has been shown to be curative in an otherwise lethal viral model without the need for extensive supportive care. This positions CPMA as a game-changer for high-risk populations, particularly puppies in shelters, breeding kennels, or resource-limited settings where sophisticated intensive care may be unavailable or cost-prohibitive. While the study was conducted in a controlled environment with early intervention (Day 4 post-challenge), real-world use will likely involve administration at the time of diagnosis, which often occurs when clinical signs are already manifest. Nevertheless, the high degree of protection (100% survival) even without concurrent supportive care suggests substantial therapeutic latitude.

Adjunctive and Emerging Therapies: Fecal Microbiota Transplantation and Organ Support

While monoclonal antibodies represent a direct antiviral strategy, other adjunctive approaches have sought to restore intestinal homeostasis and mitigate organ dysfunction. A particularly promising intervention is fecal microbiota transplantation (FMT). The pathobiology of CPV enteritis involves not only direct viral cytopathology but also a catastrophic disruption of the commensal intestinal microbiota. The loss of crypt epithelium, coupled with antibiotic use, creates a dysbiotic state that may perpetuate inflammation and delay mucosal healing. In a randomized clinical trial involving 66 puppies with confirmed CPV-2b infection, Pereira et al. (2018) evaluated the addition of a single rectal FMT (10 g of feces from a healthy donor dog diluted in saline) to standard intravenous fluid and antimicrobial therapy [58].

The results were notable: among survivors, FMT-treated puppies had a significantly faster resolution of diarrhea (median, 3 days vs. 6 days; P < 0.001) and shorter hospitalization time (median, 3 days vs. 6 days; P = 0.001) compared to the standard treatment group [58]. While the mortality rate was lower in the FMT group (21.2% vs. 36.4%), this difference did not reach statistical significance (P = 0.174), likely due to the sample size. The mechanism is hypothesized to involve re-establishment of a competitive and metabolically beneficial microbial community that restores short-chain fatty acid production, enhances mucus barrier function, and outcompetes pathogenic bacteria, thereby reducing ongoing intestinal inflammation and promoting villus regeneration [58]. This is particularly relevant given that even after clinical recovery from CPV, dogs are at increased risk for chronic gastrointestinal disease, suggesting that early microbial restoration may have long-term protective effects [47].

Supportive management must also address the insidious development of acute kidney injury (AKI). Conventional renal biomarkers (serum creatinine and urea) frequently fail to detect early injury in CPV patients because these dogs are often hypoproteinemic and have low muscle mass, masking creatinine elevations [50]. However, studies using novel urinary biomarkers, including retinol-binding protein (uRBP), neutrophil gelatinase-associated lipocalin (uNGAL), urinary immunoglobulin G (uIgG), and urinary C-reactive protein (uCRP), have revealed that CPV-infected dogs consistently exhibit evidence of both glomerular and tubular injury [50]. This subclinical AKI is likely multifactorial, stemming from severe dehydration, hypotension due to SIRS, and sepsis-induced microvascular thrombosis. Therefore, any modern treatment protocol must include meticulous fluid balance monitoring, avoidance of nephrotoxic drugs (e.g., aminoglycosides, NSAIDs), and consideration of early renal replacement therapy in oliguric patients.

The Evolving Viral Landscape: Implications for Treatment Efficacy and Vaccine Failure

A critical consideration for any therapeutic or prophylactic strategy is the rapidly evolving antigenic landscape of CPV-2. The original CPV-2 strain that emerged in 1978 has been completely replaced by three antigenic variants, CPV-2a, CPV-2b, and CPV-2c, based on amino acid substitutions at residue 426 of the VP2 capsid protein [2, 14, 35]. Globally, the distribution of these variants is dynamic and regionally specific. CPV-2c has become the predominant or co-dominant variant in many regions, including China, Vietnam, Taiwan, Nigeria, Italy, and parts of South America [7, 20, 22, 23, 28, 65]. Crucially, these recent CPV-2c strains frequently carry additional mutations beyond the defining 426Glu residue, including A5G, F267Y, Y324I, and Q370R, which are characteristic of an Asian-origin clade that is now spreading to Europe and Africa [6, 17, 18, 30].

The clinical relevance of these mutations is profound. The VP2 protein is the primary target of neutralizing antibodies, and these substitutions occur in or adjacent to major antigenic epitopes and the transferrin receptor binding site [8, 15]. This has led to documented antigenic drift, where the immunity provided by vaccines based on older CPV-2 or CPV-2a strains may be suboptimal against contemporary CPV-2c field strains. This is supported by epidemiological data showing that vaccine failure is common: in one Australian survey, veterinarians reported that 48.7% of puppies were receiving their final vaccination earlier than recommended by guidelines, exacerbating the risk of a window of susceptibility [26]. Furthermore, sequence analysis reveals that vaccinated dogs can still become infected and shed high levels of CPV-2c, albeit with higher Ct values (lower viral load) than unvaccinated dogs [21]. The phenomenon of vaccine failure is primarily attributed to interference by maternally derived antibodies (MDA), but the emergence of antigenically distinct variants that evade vaccine-induced immunity is an increasingly recognized factor [5, 8, 21].

This evolving landscape directly impacts the design and efficacy of monoclonal antibody therapies. The CPMA product evaluated by Larson et al. was developed against a specific CPV-2b challenge strain [44]. For such therapy to maintain broad clinical utility, it must demonstrate cross-neutralizing activity against the major circulating variants, particularly the diverse CPV-2c strains. The high conservation of the transferrin receptor binding interface (the "canyon" motif on VP2) is promising, as many neutralizing antibodies target this functionally constrained region [52]. However, the rapid fixation of mutations at residues 267, 324, and 370 in Asian-origin CPV-2c strains [6, 18, 30] necessitates ongoing surveillance to verify that monoclonal antibodies currently in development or licensure retain efficacy against these emerging lineages. If monoclonal antibodies are derived from immunization with a single variant, there is a potential for epitope mismatch, leading to reduced neutralization of heterogeneous field strains. Therefore, next-generation monoclonal cocktails or broadly neutralizing antibodies targeting conserved epitopes should be considered a priority for future research and regulatory approval.

In summary, the treatment of CPV has evolved from a purely supportive endeavor to one that now includes highly effective passive immunotherapy. The advent of a single-dose monoclonal antibody that prevented mortality in an experimental setting represents a landmark achievement. However, the successful translation of this therapy into clinical practice will depend on its activity against the ever-changing viral landscape, its affordability for widespread use in shelters and underserved populations, and its integration into protocols that also address the acute kidney injury and long-term gastrointestinal consequences of infection. The interplay between viral evolution, vaccine failure, and therapeutic efficacy remains the central challenge for veterinary medicine in the coming decade.

Prevention and Vaccination Strategies for Canine Parvovirus

The Imperative of Overcoming Maternally Derived Antibody Interference

The cornerstone of canine parvovirus (CPV-2) prevention remains prophylactic vaccination, yet the persistence of disease globally underscores a fundamental immunological bottleneck: the interference by maternally derived antibodies (MDA). Despite the availability of highly efficacious vaccines, immunization failures are a pervasive clinical reality, with MDA interference recognized as the single most important cause of these failures [5, 26]. The window of susceptibility, the period between the waning of passive immunity from the dam and the establishment of a robust active immune response in the puppy, represents a critical vulnerability. Standard vaccination protocols, typically commencing at 6–8 weeks of age with boosters every 3–4 weeks until 16–20 weeks, are designed to close this gap. However, high titers of MDA, which vary considerably among individual puppies depending on the dam’s vaccination history and colostral intake, can neutralize vaccine antigens, preventing seroconversion and leaving the puppy unprotected [5].

A paradigm shift in addressing this challenge has been the development of a novel recombinant CPV-2c vaccine strain, designated 630a, which has been formulated into a bivalent vaccine (Nobivac DP PLUS) with a canine distemper virus component [66]. The mechanistic basis for its unique efficacy lies in its ability to induce sterilizing immunity as early as three days post-vaccination in naïve animals and, critically, to overcome very high levels of MDA from as early as four weeks of age [66]. This is a profound advancement, as traditional modified-live virus (MLV) vaccines are often neutralized by MDA present at that age. The 630a strain, derived from the structural and non-structural elements of an established type 2 backbone but engineered as a recombinant type 2c, appears to possess a replication advantage or altered antigenic presentation that allows it to infect host cells and stimulate an effective immune response even in the presence of circulating passive antibodies. This strategy directly targets the immunity gap, suggesting that future vaccine development should prioritize strains with enhanced immunogenicity in the neonate, effectively closing the window of susceptibility before natural exposure occurs [5, 66].

Antigenic Drift and the Need for Updated Vaccine Strain Composition

A second, equally pressing challenge to CPV prevention is the continuous antigenic drift of circulating field strains away from the original vaccine antigens. Since the emergence of CPV-2 in 1978, the virus has undergone significant evolution, with the original type being completely replaced by three antigenic variants: CPV-2a, CPV-2b, and CPV-2c [2, 14, 40]. Current epidemiological surveillance reveals a dynamic global landscape. CPV-2c has demonstrated a clear tendency to replace CPV-2a as the new dominant variant in Asia, South America, North America, and parts of Africa [2, 7, 22, 23, 39]. Furthermore, a distinct Asian-origin CPV-2c lineage, characterized by specific amino acid substitutions in the VP2 capsid protein (including A5G, F267Y, Y324I, and Q370R), is progressively expanding its geographic range, having now been documented in dogs in Europe (e.g., Italy, Romania) and Africa (e.g., Nigeria) [6, 17, 22, 30].

The critical concern from a vaccination perspective is that these mutations occur in the major antigenic regions of the VP2 protein, which are the primary targets of vaccine-induced neutralizing antibodies. Studies have identified positive selection pressure at specific sites (e.g., VP2 residues 297, 324, 426, and 440), which are directly associated with immune evasion via antigenic drift [8, 40]. The detection of CPV-2c as the dominant subtype infecting both vaccinated and unvaccinated dogs in Australia, and the identification of vaccine failure cases associated with CPV-2c, provides compelling field evidence that current vaccines may not provide optimal protection against all circulating variants [21, 67]. While many current vaccines contain CPV-2 or CPV-2a/b strains and can still provide cross-protection against heterologous variants, the degree of protection may be incomplete, particularly against the novel Asian CPV-2c lineage [1, 6]. This underscores an urgent need for regulatory authorities and vaccine manufacturers to continuously monitor variant prevalence and consider incorporating updated strains, such as the aforementioned 630a CPV-2c strain, into routine immunization protocols to ensure broad and durable population-level immunity [1, 35, 66].

Biosecurity, Disinfection, and One Health Considerations

Prevention cannot rely on vaccination alone, particularly in high-risk environments such as shelters, kennels, and breeding facilities. CPV is an exceptionally hardy, non-enveloped virus that can persist in the environment for months to years, surviving on fomites, flooring, and soil [14, 36]. Effective environmental decontamination is therefore a critical adjunct to vaccination. Among disinfectants, sodium hypochlorite (bleach) remains the gold standard. Rigorous in vitro studies have demonstrated that a 0.75% solution with a contact time of just one minute can significantly reduce viral titers, while a 0.37% solution is effective if the contact time is extended to 15 minutes [36]. Crucially, the presence of organic matter (e.g., feces, vomitus) completely abrogates the virucidal activity of sodium hypochlorite, emphasizing that thorough cleaning with a detergent to remove organic debris must precede disinfection [36]. This principle is non-negotiable in outbreak management.

The One Health dimension of CPV prevention is increasingly apparent, given the documented spillover of CPV-2 into a wide range of wildlife species, including coyotes, foxes, African lions, pangolins, river otters, and even pigs [3, 4, 9, 24, 25, 32, 53]. The presence of antibodies to CPV in a high percentage of free-ranging coyotes and foxes in Pennsylvania (45.5% and 52.4–68.8%, respectively) demonstrates sustained circulation in sylvatic cycles [3]. This wildlife reservoir poses a continuous risk of re-introduction into domestic dog populations, particularly in peri-urban and rural areas where contact is more likely. Furthermore, the detection of CPV-2c in Taiwanese pangolins, a non-carnivore, highlights the potential for cross-species transmission into vulnerable or endangered species [9, 25]. Consequently, comprehensive prevention strategies must integrate vaccination of domestic dogs to reduce the viral load in the environment, coupled with surveillance of wildlife populations to monitor for spillover events and the emergence of novel variants that could further challenge vaccine efficacy [3, 24].

Surveillance, Diagnostics, and Vaccine Policy

A robust prevention framework is dependent on accurate surveillance and diagnostics, which inform vaccine policy and outbreak response. Molecular epidemiological surveys, using complete VP2 gene sequencing or whole-genome sequencing, are essential to track the spatiotemporal distribution of CPV variants and detect the emergence of potentially vaccine-escape mutants [27, 34, 67]. For example, studies in China, Thailand, and Italy have all documented a dynamic shift towards CPV-2c, replacing previously dominant CPV-2a strains, a trend that would be invisible without continuous genomic monitoring [7, 28, 54].

Diagnostic challenges, particularly with point-of-care antigen tests, have direct implications for prevention. A significant proportion of CPV-2c-infected dogs can test negative on fecal antigen ELISA tests, likely due to lower viral shedding or antigenic variation affecting test antibody binding [21]. This can lead to false-negative results, delayed diagnosis, and continued environmental contamination, thereby undermining biosecurity efforts. Molecular methods such as quantitative PCR (qPCR) and recombinase polymerase amplification (RPA) offer superior sensitivity and specificity and should be considered the gold standard for case confirmation, especially in settings where vaccination status is unknown or where clinical suspicion is high despite a negative antigen test [21, 63, 64]. In the context of global movement of dogs, which can introduce novel strains across borders (e.g., Asian CPV-2c into Europe), the role of import screening and quarantine becomes a tangible prevention tool [30]. Ultimately, the goal of disease eradication, while challenging, requires a coordinated global effort that combines high-coverage vaccination with updated strains, rigorous biosecurity, and active molecular surveillance to detect and contain emerging threats [5, 29]. The socioeconomic drivers of infection, including poverty and limited access to veterinary care, must also be addressed, as they are the strongest risk factors for CPV cases and euthanasia, particularly in rural and remote communities [26, 29].

References

[1] Temizkan M, Temizkan SS. Canine Parvovirus in Turkey: First Whole-Genome Sequences, Strain Distribution, and Prevalence. Viruses. 2023. DOI: https://doi.org/10.3390/v15040957

[2] Hao X, Li Y, Xiao X, Chen B, Zhou P, Li S. The Changes in Canine Parvovirus Variants over the Years. International Journal of Molecular Sciences. 2022. DOI: https://doi.org/10.3390/ijms231911540

[3] Kimpston CN, Hatke AL, Castelli B, Otto N, Tiffin HS, Machtinger E, et al.. High Prevalence of Antibodies against Canine Parvovirus and Canine Distemper Virus among Coyotes and Foxes from Pennsylvania: Implications for the Intersection of Companion Animals and Wildlife. Microbiology spectrum. 2022. DOI: https://doi.org/10.1128/spectrum.02532-21

[4] Temeeyasen G, Sharafeldin T, Lin C, Hause B. Spillover of Canine Parvovirus Type 2 to Pigs, South Dakota, USA, 2020. Emerging Infectious Diseases. 2022. DOI: https://doi.org/10.3201/eid2802.211681

[5] Decaro N, Buonavoglia C, Barrs V. Canine parvovirus vaccination and immunisation failures: Are we far from disease eradication?. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108760

[6] Balboni A, Niculae M, Vito SD, Urbani L, Terrusi A, Mureșan C, et al.. The detection of canine parvovirus type 2c of Asian origin in dogs in Romania evidenced its progressive worldwide diffusion. BMC Veterinary Research. 2021. DOI: https://doi.org/10.1186/s12917-021-02918-6

[7] Chen B, Zhang X, Zhu J, Liao L, Bao E. Molecular Epidemiological Survey of Canine Parvovirus Circulating in China from 2014 to 2019. Pathogens. 2021. DOI: https://doi.org/10.3390/pathogens10050588

[8] Alexis V, Sonia V, Daniela S, Miguel G, Timothy H, Valentina F, et al.. Molecular Analysis of Full-Length VP2 of Canine Parvovirus Reveals Antigenic Drift in CPV-2b and CPV-2c Variants in Central Chile. Animals. 2021. DOI: https://doi.org/10.3390/ani11082387

[9] Chang Y, Lin Z, Lin Y, Lin K, Chan F, Hsiao S, et al.. Canine Parvovirus Infections in Taiwanese Pangolins (Manis pentadactyla pentadactyla). Veterinary Pathology-Supplement. 2021. DOI: https://doi.org/10.1177/03009858211002198

[10] Arora R, Malla WA, Tyagi A, Mahajan S, Sajjanar B, Tiwari A. Canine Parvovirus and Its Non-Structural Gene 1 as Oncolytic Agents: Mechanism of Action and Induction of Anti-Tumor Immune Response. Frontiers in Oncology. 2021. DOI: https://doi.org/10.3389/fonc.2021.648873

[11] Qi S, Zhao J, Guo D, Sun D. A Mini-Review on the Epidemiology of Canine Parvovirus in China. Frontiers in Veterinary Science. 2020. DOI: https://doi.org/10.3389/fvets.2020.00005

[12] Mia M, Hasan M. Update on Canine Parvovirus Infection: A Review from the Literature. Veterinary Sciences: Research and Reviews. 2021. DOI: https://doi.org/10.17582/journal.vsrr/2021.7.2.92.100

[13] Singh P, Kaur G, Chandra M, Dwivedi P. Prevalence and molecular characterization of canine parvovirus. Veterinary World. 2021. DOI: https://doi.org/10.14202/vetworld.2021.603-606

[14] Jumaa R, Abdulmjeed DI, Mohsin SI, Atshan OF. Canine parvovirus: A review. International Journal of Science and Research Archive. 2021. DOI: https://doi.org/10.30574/ijsra.2021.3.2.0140

[15] Voorhees IEH, Lee H, Allison AB, López-Astacio RA, Goodman L, Oyesola O, et al.. Limited Intrahost Diversity and Background Evolution Accompany 40 Years of Canine Parvovirus Host Adaptation and Spread. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.01162-19

[16] Giraldo-Ramirez S, Rendon-Marin S, Ruíz-Sáenz J. Phylogenetic, Evolutionary and Structural Analysis of Canine Parvovirus (CPV-2) Antigenic Variants Circulating in Colombia. Viruses. 2020. DOI: https://doi.org/10.3390/v12050500

[17] Mira F, Purpari G, Bella SD, Colaianni ML, Schiró G, Chiaramonte G, et al.. Spreading of canine parvovirus type 2c mutants of Asian origin in southern Italy. Transboundary and Emerging Diseases. 2019. DOI: https://doi.org/10.1111/tbed.13283

[18] Moon B, Jang J, Kim S, Kim Y, Lee H, So B, et al.. Genetic characterization of canine parvovirus type 2c from domestic dogs in Korea. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13501

[19] Horecka K, Porter S, Amirian E, Jefferson E. A Decade of Treatment of Canine Parvovirus in an Animal Shelter: A Retrospective Study. Animals. 2020. DOI: https://doi.org/10.3390/ani10060939

[20] Charoenkul K, Tangwangvivat R, Janetanakit T, Boonyapisitsopa S, Bunpapong N, Chaiyawong S, et al.. Emergence of canine parvovirus type 2c in domestic dogs and cats from Thailand. Transboundary and Emerging Diseases. 2019. DOI: https://doi.org/10.1111/tbed.13177

[21] Yip HY, Peaston A, Woolford L, Khuu SJ, Wallace G, Kumar RS, et al.. Diagnostic Challenges in Canine Parvovirus 2c in Vaccine Failure Cases. Viruses. 2020. DOI: https://doi.org/10.3390/v12090980

[22] Ogbu K, Mira F, Purpari G, Nwosuh C, Loria G, Schiró G, et al.. Nearly full‐length genome characterization of canine parvovirus strains circulating in Nigeria. Transboundary and Emerging Diseases. 2019. DOI: https://doi.org/10.1111/tbed.13379

[23] Hoang M, Lin W, Le V, Nga BT, Chiou M, Lin C. Molecular epidemiology of canine parvovirus type 2 in Vietnam from November 2016 to February 2018. Virology Journal. 2019. DOI: https://doi.org/10.1186/s12985-019-1159-z

[24] Behdenna A, Lembo T, Calatayud O, Cleaveland S, Halliday JEB, Packer C, et al.. Transmission ecology of canine parvovirus in a multi-host, multi-pathogen system. Proceedings of the Royal Society B. 2019. DOI: https://doi.org/10.1098/rspb.2018.2772

[25] Wang S, Tu Y, Lee M, Wu L, Chen T, Wu C, et al.. Fatal Canine Parvovirus-2 (CPV-2) Infection in a Rescued Free-ranging Taiwanese Pangolin (Manis pentadactyla pentadactyla).. Transboundary and Emerging Diseases. 2019. DOI: https://doi.org/10.1111/tbed.13469

[26] Kelman M, Barrs V, Norris J, Ward M. Canine parvovirus prevention and prevalence: Veterinarian perceptions and behaviors.. Preventive Veterinary Medicine. 2019. DOI: https://doi.org/10.1016/j.prevetmed.2019.104817

[27] Franzo G, Tucciarone C, Casagrande S, Caldin M, Cortey M, Furlanello T, et al.. Canine parvovirus (CPV) phylogeny is associated with disease severity. Scientific Reports. 2019. DOI: https://doi.org/10.1038/s41598-019-47773-6

[28] Battilani M, Modugno F, Mira F, Purpari G, Bella SD, Guercio A, et al.. Molecular epidemiology of canine parvovirus type 2 in Italy from 1994 to 2017: recurrence of the CPV-2b variant. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-2096-1

[29] Kelman M, Barrs V, Norris J, Ward M. Socioeconomic, geographic and climatic risk factors for canine parvovirus infection and euthanasia in Australia. Preventive Veterinary Medicine. 2019. DOI: https://doi.org/10.1016/j.prevetmed.2019.104816

[30] Mira F, Purpari G, Lorusso E, Bella S, Gucciardi F, Desario C, et al.. Introduction of Asian canine parvovirus in Europe through dog importation. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12747

[31] Sun Y, Cheng Y, Lin P, Zhang H, Yi L, Tong M, et al.. Simultaneous detection and differentiation of canine parvovirus and feline parvovirus by high resolution melting analysis. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-1898-5

[32] Oosthuizen A, Brettschneider H, Dalton D, Plessis ECD, Jansen R, Kotzé A, et al.. Canine parvovirus detected from a serval (Leptailurus serval) in South Africa. Journal of the South African Veterinary Association. 2019. DOI: https://doi.org/10.4102/jsava.v90i0.1671

[33] Grecco S, Iraola G, Decaro N, Alfieri A, Alfieri A, Calderón MG, et al.. Inter- and intracontinental migrations and local differentiation have shaped the contemporary epidemiological landscape of canine parvovirus in South America. Virus Evolution. 2018. DOI: https://doi.org/10.1093/ve/vey011

[34] Tucciarone C, Franzo G, Mazzetto E, Legnardi M, Caldin M, Furlanello T, et al.. Molecular insight into Italian canine parvovirus heterogeneity and comparison with the worldwide scenario.. Infection, Genetics and Evolution. 2018. DOI: https://doi.org/10.1016/j.meegid.2018.09.021

[35] Zhou P, Zeng W, Zhang X, Li S. The genetic evolution of canine parvovirus – A new perspective. PLoS ONE. 2017. DOI: https://doi.org/10.1371/journal.pone.0175035

[36] Cavalli A, Marinaro M, Desario C, Corrente M, Camero M, Buonavoglia C. In vitro virucidal activity of sodium hypochlorite against canine parvovirus type 2. Epidemiology and Infection. 2018. DOI: https://doi.org/10.1017/S0950268818002431

[37] Kelman M, Ward M, Barrs V, Norris J. The geographic distribution and financial impact of canine parvovirus in Australia. Transboundary and Emerging Diseases. 2018. DOI: https://doi.org/10.1111/tbed.13022

[38] Hoang M, Wu H, Lien Y, Chiou M, Lin C. A SimpleProbe® real‐time PCR assay for differentiating the canine parvovirus type 2 genotype. Journal of clinical laboratory analysis (Print). 2018. DOI: https://doi.org/10.1002/jcla.22654

[39] Lin Y, Chiang S, Wu H, Lin J, Chiou M, Liu H, et al.. Phylodynamic and Genetic Diversity of Canine Parvovirus Type 2c in Taiwan. International Journal of Molecular Sciences. 2017. DOI: https://doi.org/10.3390/ijms18122703

[40] Li G, Ji S, Zhai X, Zhang Y, Liu J, Zhu M, et al.. Evolutionary and genetic analysis of the VP2 gene of canine parvovirus. BMC Genomics. 2017. DOI: https://doi.org/10.1186/s12864-017-3935-8

[41] Ravi A, Ereqat S, Al-Jawabreh A, Abdeen Z, Shamma OAA, Hall H, et al.. Metagenomic profiling of ticks: Identification of novel rickettsial genomes and detection of tick-borne canine parvovirus. bioRxiv. 2018. DOI: https://doi.org/10.1371/journal.pntd.0006805

[42] Folitse R, Kodie D, Amemor E, Dei D, Tasiame W, Burimuah V, et al.. DETECTION OF CANINE PARVOVIRUS ANTIGEN IN DOGS IN KUMASI, GHANA. African Journal of Infectious Diseases. 2017. DOI: https://doi.org/10.21010/ajid.v12i1.5

[43] Chiang S, Wu H, Chiou M, Chang M, Lin C. Identification of a novel canine parvovirus type 2c in Taiwan. Virology Journal. 2016. DOI: https://doi.org/10.1186/s12985-016-0620-5

[44] Larson L, Miller L, Margiasso M, Piontkowski MD, Tremblay D, Dykstra S, et al.. Early administration of canine parvovirus monoclonal antibody prevented mortality after experimental challenge.. Journal of the American Veterinary Medical Association. 2024. DOI: https://doi.org/10.2460/javma.23.09.0541

[45] Jing Z, Ji P, Wei Y, Hao F, Wei Y. Isolation and identification of a novel canine parvovirus type 2c strain in domestic cats in Dalian, China. Frontiers in Veterinary Science. 2022. DOI: https://doi.org/10.3389/fvets.2022.1001604

[46] Alves F, Prata S, Nunes T, Gomes J, Aguiar S, Silva FD, et al.. Canine parvovirus: a predicting canine model for sepsis. BMC Veterinary Research. 2020. DOI: https://doi.org/10.1186/s12917-020-02417-0

[47] Kilian E, Suchodolski J, Hartmann K, Mueller R, Wess G, Unterer S. Long-term effects of canine parvovirus infection in dogs. PLoS ONE. 2018. DOI: https://doi.org/10.1371/journal.pone.0192198

[48] Headley SA, Oliveira TE, Pereira AHT, Moreira JR, Michelazzo MZ, Pires BG, et al.. Canine morbillivirus (canine distemper virus) with concomitant canine adenovirus, canine parvovirus-2, and Neospora caninum in puppies: a retrospective immunohistochemical study. Scientific Reports. 2018. DOI: https://doi.org/10.1038/s41598-018-31540-0

[49] Zhao H, Wang J, Jiang Y, Cheng Y, Lin P, Zhu H, et al.. Typing of Canine Parvovirus Strains Circulating in North‐East China. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12390

[50] Berg M, Schoeman J, Defauw P, Whitehead Z, Breemersch A, Goethals K, et al.. Assessment of acute kidney injury in canine parvovirus infection: Comparison of kidney injury biomarkers with routine renal functional parameters.. The Veterinary Journal. 2018. DOI: https://doi.org/10.1016/j.tvjl.2018.10.002

[51] Oliveira PSBd, Cargnelutti J, Masuda E, Fighera R, Kommers G, Silva M, et al.. Epidemiological, clinical and pathological features of canine parvovirus 2c infection in dogs from southern Brazil. Pesquisa Veterinaria Brasileira. 2018. DOI: https://doi.org/10.1590/1678-5150-PVB-5122

[52] Dunbar CA, Callaway H, Parrish C, Jarrold M. Probing Antibody Binding to Canine Parvovirus with Charge Detection Mass Spectrometry.. Journal of the American Chemical Society. 2018. DOI: https://doi.org/10.1021/jacs.8b08050

[53] Echenique J, Soares MP, Mascarenhas CS, Bandarra P, Quadros PA, Driemeier D, et al.. Lontra longicaudis infected with canine parvovirus and parasitized by Dioctophyma renale. Pesquisa Veterinária Brasileira. 2018. DOI: https://doi.org/10.1590/1678-5150-PVB-5744

[54] Inthong N, Kaewmongkol S, Meekhanon N, Sirinarumitr K, Sirinarumitr T. Dynamic evolution of canine parvovirus in Thailand. Veterinary World. 2020. DOI: https://doi.org/10.14202/vetworld.2020.245-255

[55] Polat P, Şahan A, Aksoy G, Timurkan M, Dinçer E. Molecular and restriction fragment length polymorphism analysis of canine parvovirus 2 (CPV-2) in dogs in southeast Anatolia, Turkey. Onderstepoort Journal of Veterinary Research. 2019. DOI: https://doi.org/10.4102/ojvr.v86i1.1734

[56] Giudici S, Cubeddu T, Giagu A, Sanna G, Rocca S, Oggiano A. First molecular characterization of canine parvovirus strains in Sardinia, Italy. Archives of Virology. 2017. DOI: https://doi.org/10.1007/s00705-017-3457-3

[57] Faraji R, Sadeghi M, Mozhgani S, Vasinioti V, Ndiana LA, Desario C, et al.. Detection of canine circovirus in dogs infected with canine parvovirus.. Acta Tropica. 2022. DOI: https://doi.org/10.1016/j.actatropica.2022.106646

[58] Pereira GQ, Gomes LA, Santos IS, Alfieri A, Weese JS, Costa MC. Fecal microbiota transplantation in puppies with canine parvovirus infection. Journal of Veterinary Internal Medicine. 2018. DOI: https://doi.org/10.1111/jvim.15072

[59] Hasan MM, Jalal M, Bayzid M, Sharif M, Masuduzzaman M. A COMPARATIVE STUDY ON CANINE PARVOVIRUS INFECTION OF DOG IN BANGLADESH AND INDIA. Bangladesh Journal of Veterinary Medicine. 2017. DOI: https://doi.org/10.3329/BJVM.V14I2.31403

[60] Li C, Tang J, Chen Z, Niu G, Liu G. A divergent canine parvovirus type 2c (CPV-2c) isolate circulating in China.. Infection, Genetics and Evolution. 2019. DOI: https://doi.org/10.1016/j.meegid.2019.05.004

[61] Khan H, Khan A, Liu Y, Wang S, Bibi S, Xu H, et al.. CRISPR-Cas13a mediated nanosystem for attomolar detection of canine parvovirus type 2. Chinese chemical letters = Zhongguo hua xue kuai bao. 2019. DOI: https://doi.org/10.1016/j.cclet.2019.10.032

[62] Sun Y, Cheng Y, Lin P, Yi L, Tong M, Cao Z, et al.. A multiplex TaqMan real-time PCR for detection and differentiation of four antigenic types of canine parvovirus in China. Molecular and Cellular Probes. 2018. DOI: https://doi.org/10.1016/j.mcp.2018.02.004

[63] Liu L, Wang J, Geng Y, Wang J, Li R, Shi R, et al.. Equipment-free recombinase polymerase amplification assay using body heat for visual and rapid point-of-need detection of canine parvovirus 2. Molecular and Cellular Probes. 2018. DOI: https://doi.org/10.1016/j.mcp.2018.04.004

[64] Geng Y, Wang J, Liu L, Lu Y, Tan K, Chang Y. Development of real-time recombinase polymerase amplification assay for rapid and sensitive detection of canine parvovirus 2. BMC Veterinary Research. 2017. DOI: https://doi.org/10.1186/s12917-017-1232-z

[65] Torre DL, Mafla E, Puga B, Erazo L, Astolfi-Ferreira C, Ferreira AP. Molecular characterization of canine parvovirus variants (CPV-2a, CPV-2b, and CPV-2c) based on the VP2 gene in affected domestic dogs in Ecuador. Veterinary World. 2018. DOI: https://doi.org/10.14202/vetworld.2018.480-487

[66] Pearce J, Spibey N, Sutton D, Tarpey I. Development of a Novel Canine Parvovirus Vaccine Capable of Stimulating Protective Immunity in Four-Week-Old Puppies in the Face of High Levels of Maternal Antibodies. Vaccines. 2023. DOI: https://doi.org/10.3390/vaccines11091499

[67] Parker J, Murphy M, Hueffer K, Chen J. Investigation of a Canine Parvovirus Outbreak using Next Generation Sequencing. Scientific Reports. 2017. DOI: https://doi.org/10.1038/s41598-017-10254-9